A B S T R A C T Gastric inhibitory polypeptide (GIP) is considered to be the principal mediator of the enteroinsular axis. A glucose-insulin clamp technique was used to study the effects of differing blood glucose levels on the insulinotropic and glucagonotropic actions of fat-stimulated GIP in seven healthy subjects, as well as the effect of physiologic hyperinsulinemia on GIP secretion. Blood glucose levels were clamped for 4 h at 43+2 mg/dl (hypoglycemic clamp), 88+1 mg/dl (euglycemic clamp), and 141+2 mg/dl (hyperglycemic clamp) in the presence of a constant insulin infusion (100 mU/kg per h).
A B S T R A C T Gastric inhibitory polypeptide (GIP) is considered to be the principal mediator of the enteroinsular axis. A glucose-insulin clamp technique was used to study the effects of differing blood glucose levels on the insulinotropic and glucagonotropic actions of fat-stimulated GIP in seven healthy subjects, as well as the effect of physiologic hyperinsulinemia on GIP secretion. Blood glucose levels were clamped for 4 h at 43+2 mg/dl (hypoglycemic clamp), 88+1 mg/dl (euglycemic clamp), and 141+2 mg/dl (hyperglycemic clamp) in the presence of a constant insulin infusion (100 mU/kg per h).
Under hypoglycemic clamp conditions there was no increase in C-peptide nor glucagon after Lipomul ingestion, despite an increase of GIP of 51.7±8.7 ng/ml per 120 min. Under euglycemic clamp conditions, small and inconsistent increases in C-peptide and glucagon were observed after fat ingestion and a concomitant increase of GIP of 35.2±9.4 ng/ml per 120 min. Under hyperglycemic clamp conditions after fat ingestion and a GIP increase of 24 .0±5.7 ng/ml per 120 min, C-peptide increased from 6.4±5 ng/ml to 11.0±1.1 ng/ml (P < 0.01) but glucagon did not change. These findings confirm that in healthy man GIP exerts its insulinotropic properties only under hyperglycemic conditions and indicate that GIP is not glucagonotropic.
Under euglycemic clamp conditions (plasma glucose, 89±1 mg/dl) and physiologic hyperinsulinemia (serum immunoreactive insulin, 137±3 ,uU/ml) GIP responses to fat ingestion (39.7±9.8 ng/ml per 120 min) were not different from the GIP responses to fat ingestion in the absence of hyperinsulinemia (39.7±11.1 ng/ml per 120 min). Therefore, insulin under normogly-
INTRODUCTION
Gastric inhibitory polypeptide (GIP)' is considered to be the gastrointestinal factor primarily responsible for the greater plasma insulin response to oral compared to parenteral nutrient administration (1) (2) (3) . Although ingestion ofcarbohydrate, fat (4) , and some amino acids (5) results in increased levels of GIP, increased levels of insulin are observed only after oral carbohydrate (4) and amino acid (5) and not after oral fat (4) . These observations suggest that the insulin secretory responsiveness of the beta cell to GIP is influenced by substrate or hormonal factors. There is in vitro evidence that the insulinogenic effect of GIP is glucose dependent (2, 6) . Studies in humans, however, have shown conflicting results. There is evidence, using a glucose clamp technique, that the insulinotropic action of oral glucose-stimulated GIP (7) occurs only during hyperglycemia, but also evidence that amino acid-stimulated GIP is insulinotropic in the absence of hyperglycemia (5, 8) . The involvement ofa glucose-dependent mechanism for the insulinotropic action of fat-stimulated GIP has been reported from nonsteady-state conditions (8-10), but has not been investigated using a glucose clamp.
Whether insulin released after nutrient ingestion also regulates the secretion of GIP as part of a negative feedback system is presently controversial. The reduced GIP responses to oral fat observed after an intra-'Abbreviation uised in this )ai)er: GIP, gastric inhibitory polypeptide.
Venous bolus of insulin or durinlg a coIncomitant infuision of gIlucose supported an inhibitorx action of insulin on the secretioni of GIP (4, (8) (9) (10) (11) . However, Andersen et al. (7) , using a glucose-insulin clacmp technique at euglycem-nia and hyperglycemia, fouind no feedback inhib)ition of insulin on glucose-stimultlated GIP secretioll.
The eurrent studies were undertaken to examine whether the level of glycemia moduilates the insulinotropic effect of fat-stimulated GIP, to determine whether insulin inhibits the secretion of fat-stimulated GIP, anid to determine wvhether the level of glycemia itself miav inifluence the GIP responise to oral fat. GIP, C-peptide, and glucagon responsies to fat ingestion Nere imieastured in healthy subjects while glycemiia was miiaintainied by a glucose-insulin clamiip techni(lue in the hypoglycemic, euglycemic, and hyperglycemic ranges durinig a concomitant inftusion of insulin at a rate sufficienit to achieve physiologic hvperinssulinemnia.
METHODS
inormed conisenit was obtained fromil seven iioriiail nonobese sul)ects (three males, four females) ages 36±5 yr (mean ± SEM). All were within 10% of their ideal bodx weight and n1on1e had a fhimilv history of'diabetes mellitis.
Each subject was stu(die(l in the ov-ernight f:aste(d state at each glycemic clamiip level, and six of the seven subjects were studiedl dIurinig saline infusion in the absence of' glucose-insulill clamiip with and xvithout the ingestion of Lipomutl. Each study was sep)arated by 1-2 wk.
For each glucose clamp studv 18-gauge indwelling catheters were inserted into contralateral antecuibital veins, one for the conttinuous inf'usioni of crystalline insulini (pork U100, Eli Lilly & Co., Indianapolis, Ind.), at the rate of 100 mU/kg per h 1v imleanls of a Harvard pump (Harvard Apparatus, millis, NMass.) and one for the intermittent (every 20 min) wvithdrawal of' blood for the determination of hormonies. Distal to the inisilini inf'usion site in a separate f'orearmii vein, a doublelumiien caltheter was inserted for continutiouis withdrawal of )lood (at a rate of 2 ml/h for glucose analyN-sis by the Biostator.
The glucose clamp was achieved using the Biostator GCIIS (Life Science Instruments, Elkhart, Ind.), wvhich permits continuous analysis and minuite-by-minute recording of plasma glucose levels (glucose-oxidase) as well as the infuision of glucose according to predetermined computer-contained algorithlmls (12) . Glucose (50 g/dl) was inf'used through the insuilin infuision access site at rates determined by the Biostator (mode 7:1). In each subject the glucose clamp was maintainled at 45 For the two stuidies wvithout the insulini-gluicose clampii), with and without the Lipomutl ingestion, blood samiples were ohtained for 20-mimi intervals f'or glucose, insulin, and GIP determiniationis for 140 mi.
Sertum samples were f'rozen for insuilini assay. Blood samples for GIP and C-peptide were collectedl on ice in tubes conttaining EDTA andl Trasvlol (500 kallikreini inhibitor tuniits/Il; Sigmla Chemiiical Co., St. Louis, Io.) cenitrif'ugedl at 4°C after which the plasma was frozen until assay. Blood for glucagonl was processed similarly except for the use of benzamidine (0.1 M) instead of Trasvlol.
Hormonie assaqs. Plasmna GIP was measure(d bv the miiethod of' Kuzio et al. (13) . Purified GIP, obtained fromii Dr. J. C.
Brown (University of' British Columbia, \ancouver, British Coltumbia, Canca(la) was used as standardl and( tracer. Anltiserumii R4817 wxas used at a final dilution of 1:100,000. This antiserumil detects the twro molecular forms of imminuinoreactive GIP (5,000 and 7,500 mol wt) present in postprandial blood. (14) and Faloona et al. (15) , respectively.
Plasmaiit C-peptide wvas measured using the reagenits and procedure obtained from Calbiochem-Behri ng Corp., Amiierican Hoechst Corp. (San Diego, Calif.). The characteristics of the rabbit aintiserumiii against synthetic hulman C-peptide have been descril)ed (16 reached a stable plateau after 40 min (43 +2 mg/dl) with a coefficient of variation of 6.8 +8%. During the 0-120-min period, GIP levels decreased from basal values of 186±24 to 145±30 pg/ml. After Lipomul ingestion, the GIP levels increased to a maximum of 784±130 pg/ml at 220 min (P < 0.01 vs. basal). The integrated GIP response over 120 min was 51.7±8.1 ng/ml. C-peptide levels decreased from basal levels at 2.2+0.3 to 1.1±0.1 ng/ml at 120 min (P < 0.01). After Lipomul ingestion the C-peptide levels remained unchanged. Insulin levels were at a stable plateau of 144+3 ,uU/ml for the 20-120-min period and did not change after fat ingestion. Glucagon levels increased from basal levels of 111+11 pglml and peaked at 80 min at 254+29 pg/ml (P < 0.01). After Lipomul ingestion there was no further increase but a slight decrease in glucagon levels from 221+56 pglml at 120 min to 181 ±pg/ml at 240 min.
The ingestion of Lipomul did not alter the glucose requirement for maintenance of the hypoglycemic clamp (Table I) .
Euglycemic clamp. The glucose and hormone levels before and after Lipomul ingestion during the euglycemic clamp are shown in Fig. 2 . Glucose levels averaged 88±1 mg/dl throughout the clamp with a coefficient of variation of 5.1±0.4%. During the 0-120-min period, GIP decreased from 248±40 to 127±30 pg/ml. After fat ingestion, GIP increased to a maximum of 631±98 pg/ml at 240 min (P < 0.01 vs. basal). The integrated GIP response over 120 min (35.2+±9.4 ng/ml) was less than (P < 0.05) that observed in the hypoglycemia clamp (Fig. 3) . C-peptide levels decreased from basal concentrations of 1.9±2 to 1.3±0.2 ng/ml at 120 min (P < 0.02). After fat ingestion, small and inconsistent increases in C-peptide not exceeding basal levels were observed. Insulin levels were at a stable plateau of 141±2 ,uU/ml for the 20-120-mim period and remained unchanged after fat ingestion. Glucagon levels, which had decreased during the first 120 min from basal levels of 116±8 to 77±7 pg/ml (P < 0.05) showed very small and inconsistent increases of <20 pg/ml while not exceeding basal levels after fat ingestion.
After Lipomul ingestion the amount of intravenous glucose required to maintain the euglycemic clamp was greater compared to that required during the 60-120-min period (P < 0.05) (Table I ). However, it was not different when compared to the 90-120-min period (8.2±0.5 mg/kg per min).
Hyperglycemic clamp. The glucose and hormone levels before and after Lipomul ingestion during the hyperglycemic clamp are shown in Fig. 4 . Glucose levels in the 60-240-min period averaged 142+±2 mg/dl with a coefficient of variation of 4.4±.5%. During the 0-120-min period GIP decreased from basal levels of 131+25 to 78±12 pg/ml. After fat ingestion GIP levels increased to a maximiiumi) of 377+58 pg/ml at 240 min (P < 0.01). The integrated GIP response over 120 min was 24+5.7 ng/ml. Both the peak and integrated GIP responses in the hyperglycemic clampij) were less than those observed in euiglycemic clamp (P < 0.05) aind hypoglycemic clamp (P < 0.01) (Fig. 3) Glucagoin decreased from lbasal levels of 107±10 to 80±+14 pg/ml (P < 0.05) at 120 Inin anid did not change after Lipomutl ingestion.
Greater amiiotints of intravenous glucose were re-(tliire(i to maintain the hyperglycemic glucose clamp after Lipomiul ingestioin (P < 0.02) thain before (Table I) .
Saline itfusions wvith and without Lipornul ingestion. The gltucose aind hormnone concentrations during saline in1fuisioins with aindl without Lipomul ingestion in the absence of instulin-gluicose clami1ps are contrasted to the etuglycemici clamp in Fig. 5 . During the 0-120 mimi period of saline infuision without Lipomul there was no change in glucose or insulin, but there was a decrease in GIP from 253+50 to 194+43 pg/ml. For the 0-120-min period ofthe euglycemic clamp in the same six subjects GIP decreased by a similar amount from 244±+46 to 140±32 pg/nml. Duiring the saline infusion with Lipoinuil ingestion, glucose and insulin did not change after Lipomul, whereas GIP levels increased from basal levels of 181±32 pg/ml to a maximum of 809±165 
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Verdonk, Rizza, Nelson, Go, Gerich, and Service pg/ml at 240 min (P < 0.01). The integrated GIP response for the 120-min period after Lipomul ingestion, 39.7±9.8 ng/ml, in the euglycemic glucose-insulin clamp study (n = 6) was not different from that (39.7+ 1 1.1 ng/ml) during the same 120-min period after Lipomul during the saline infusion.
DISCUSSION
The hormonal interactions for glucose homeostasis are different for each major nutrient. Ingestion of carbohydrate results in an increase in plasma glucose accompanied by an increase in plasma GIP and insulin and a decrease in plasma glucagon (4) . Amino acid ingesion results in increases in plasma GIP, insulin (5), and glucagon (18) with no change in plasma glucose. Oral fat results in no changes in plasma glucose, insulin, and glucagon (4, 19) despite increases in plasma GIP (4) . Primary among the factors that may determine the insulin secretory responsiveness of the beta cell to GIP is the ambient plasma glucose concentration. Despite the report that the infusion of porcine GIP into animals (which resulted in supraphysiologic concentrations of GIP) was insulinotropic at basal blood glucose levels (20) , the infusion of porcine GIP (which results in physiologic levels of GIP) into man is insulinotropic only during hyperglycemia (1, 21) . Glucose dependency of the insulinotropic action of glucose-stimulated GIP has been demonstrated in a recent report (7) on the basis of changes in serum immunoreactive insulin (rather than C-peptide) after oral glucose during insulin-glucose clamps at euglycemia and supraphysiologic hyperglycemia. The studies reported here, using fat instead of glucose as the GIP secretagogue, demonstrate that GIP is insulinotropic during moderate hyperglycemia and not at euglycemia or moderate hypoglycemia. Whether GIP has a glucagonotropic action has not been settled. In vitro data from the perfused pancreas indicate that this effect occurs only at glucose concentrations in the perfusate below 5.5 mM (22) . In man a glucagonotropic effect of GIP has been suggested in adult-onset diabetics (9) and for some patients with cirrhosis (23) . Fat ingestion is not associated with a change in circulating glucagon. Since it is not known whether a glucagonotropic effect of GIP might be evident during hypoglycemia, i.e., whether there may be a reverse glucose dependency of the glucagonotropic action of GIP, glucagon was measured in the studies reported here. However, it was observed that fat-stimulated GIP was not glucagonotropic at any of the glucose clamp levels. The inconsistent increases in glucagon after oral fat during the euglycemic glucose-insulin clamp were very small and did not exceed basal levels. Despite the increase in glucagon in response to the lowered glucose levels in the hypoglycemic clamp, no further increase in glucagon occurred after oral fat ingestion. This contrasts to the brisk increase in the already elevated C-peptide levels that occurred after Lipomul ingestion in the hyperglycemic clamp. The decreases of C-peptide and glucagon concentrations observed during the 0-120-min period of the euglycemic clamp are consistent with the previously reported direct suppression effect of insulin on C-peptide and glucagon (24). Andersen et al. (7) have demonstrated, using a euglycemic glucose-clamp technique, that concentrations of insulin of approximately 300 ,uU/ml did not inhibit plasma GIP responses after glucose ingestion. Indirect evidence has been generated favoring an inhibition by insulin on the fat-induced release of GIP. It has been reported that a bolus injection of insulin in pharmacologic doses given coinicident with fat ingestioni blunted the subsequent increase in plasma GIP (4) . Continuous infusions of glucose given to stimulate endogenous release of insulin were found to blunt the plasma GIP response after ingestion of either fat or galactose (8) (9) (10) 25) . In all of the above studies, however, neither insulin nor glucose concentrations were maintained at steady-state levels. The cutrrent studies demonstrated no difference in fat-stimulated GIP response in the presence or absence of physiologic hyperinsulinemia Interaction of Fat-stimulated GIP on Alpha and Beta Cell Functionat euglycemia. Although the GIP levels 120 min after Lipomul were not returniing to base-line, they were close to a plateau configuirationi in the last 60 min. The observed levels likely represent maximal responses as they are similar to those reported by others after fat ingestion (8, 9, 11) . In addition, further sampling beyond 120 min was unlikely to have shown a difference in GIP between control and euglycemic clamp studies because differences observed in GIP by others between control aind glucose infusion studies occuirred before 120 min after fat or galactose ingestion. The slight decreases in basal GIP during the 120-inin preLipomul period in the presence aind absence of hyperinsulinemia may represent the effect of fasting on GIP.
The observation of a reduced GIP response after fat ingestion during hyperglycemnia compared to the response after the same stimulus in the presence of euglycemia is consistent with previous reports (8) (9) (10) 25) , but is open to an interpretation different from anl inhibition of GIP by insulin alone. The increased GIP response to oral fat during hypoglycemia coimpared to euglycemia couipled with the reduced GIP response in hyperglycemia (Fig. 3) in the presence of similar serumn insulin levels (144+3 ,uU/ml for hypoglycemiia, 141+2 ,uU/ml for etuglycemia, and 183±5 ,uU/ml for hyperglycemia) stiggests that the glucose level itself in the presence of hyperinsulinemia affects the GIP response to oral fat. Whether this effect is on one or both molecuilar species remains to be determined.
In summary, fat-stimulated GIP has insulinotropic activity that is glucose dependent, is not gluicagonotropic, is not inhibited by physiologic hyperinsuilinemia at euglycemia, but is influenced by the ambient gluicose level in the presence of hyperinsulinemia.
